Page 86 - Read Online
P. 86

Page 80                     Xu et al. J Transl Genet Genom 2023;7:87-93  https://dx.doi.org/10.20517/jtgg.2023.10

               Conflicts of interest
               All authors declared that there are no conflicts of interest.


               Ethical approval and consent to participate
               The study involving human participants was reviewed and approved by the Ethical Committee of Peking
               University First Hospital (2021 Scientific Research 074). Written informed consent to participate in this
               study was provided by the participants.

               Consent for publication
               Written informed consent was obtained from the participants for the publication of any potentially
               identifiable images or data included in this manuscript.


               Copyright
               © The Author(s) 2023.


               REFERENCES
               1.       Hill LM, Breckle R, Thomas ML, Fries JK. Polyhydramnios: ultrasonically detected prevalence and neonatal outcome. Obstet Gynecol
                   1987;69:21-5.  PubMed
               2.       Biggio JR Jr, Wenstrom KD, Dubard MB, Cliver SP. Hydramnios prediction of adverse perinatal outcome. Obstet Gynecol
                   1999;94:773-7.  DOI  PubMed
               3.       Bauserman M, Nathan R, Lokangaka A, et al. Polyhydramnios among women in a cluster-randomized trial of ultrasound during
                   prenatal care within five low and low-middle income countries: a secondary analysis of the first look study. BMC Pregnancy
                   Childbirth 2019;19:258.  DOI  PubMed  PMC
               4.       Dashe JS, McIntire DD, Ramus RM, Santos-Ramos R, Twickler DM. Hydramnios: anomaly prevalence and sonographic detection.
                   Obstet Gynecol 2002;100:134-9.  DOI  PubMed
               5.       Guibourdenche J, Bonnet-Serrano F, Younes Chaouch L, et al. Amniotic aaquaporins (AQP) in normal and pathological pregnancies:
                   interest in polyhydramnios. Reprod Sci 2021;28:2929-38.  DOI
               6.       Abele H, Starz S, Hoopmann M, Yazdi B, Rall K, Kagan KO. Idiopathic polyhydramnios and postnatal abnormalities. Fetal Diagn
                   Ther 2012;32:251-5.  DOI  PubMed
               7.       Touboul C, Boileau P, Picone O, Foix-l’Hélias L, Frydman R, Senat M. Outcome of children born out of pregnancies complicated by
                   unexplained polyhydramnios. BJOG 2007;114:489-92.  DOI  PubMed
               8.       Konrad M, Nijenhuis T, Ariceta G, et al. Diagnosis and management of Bartter syndrome: executive summary of the consensus and
                   recommendations from the European Rare Kidney Disease Reference Network Working Group for Tubular Disorders. Kidney Int
                   2021;99:324-35.  DOI
               9.       Kömhoff M, Laghmani K. Pathophysiology of antenatal Bartter’s syndrome. Curr Opin Nephrol Hypertens 2017;26:419-25.  DOI
                   PubMed
               10.      Laghmani K, Beck BB, Yang SS, et al. Polyhydramnios, transient antenatal Bartter’S syndrome, and MAGED2 mutations. N Engl J
                   Med 2016;374:1853-63.  DOI
               11.      Legrand A, Treard C, Roncelin I, et al. Prevalence of novel MAGED2 mutations in antenatal bartter syndrome. Clin J Am Soc Nephrol
                   2018;13:242-50.  DOI  PubMed  PMC
               12.      Reinalter S, Devlieger H, Proesmans W. Neonatal bartter syndrome: spontaneous resolution of all signs and symptoms. Pediatr
                   Nephrol 1998;12:186-8.  DOI  PubMed
               13.      Meyer M, Berrios M, Lo C. Transient antenatal Bartter’S syndrome: a case report. Front Pediatr 2018;6:51.  DOI  PubMed  PMC
               14.      Yang K, Huo X, Zhang Y, et al. Genetic analysis of a pedigree affected with Bartter’s syndrome. Zhonghua Yi Xue Yi Chuan Xue Za
                   Zhi 2019;36:701-3.  DOI
               15.      Takemori S, Tanigaki S, Nozu K, et al. Prenatal diagnosis of MAGED2 gene mutation causing transient antenatal Bartter syndrome.
                   Eur J Med Genet 2021;64:104308.  DOI
               16.      Ma M, Zhang M, Zhou Y, et al. A novel MAGED2 variant in a Chinese preterm newborn with transient antenatal Bartter’s syndrome
                   with 4 years follow-up. BMC Nephrol 2021;22:408.  DOI  PubMed  PMC
               17.      Arthuis CJ, Nizon M, Kömhoff M, et al. A step towards precision medicine in management of severe transient polyhydramnios:
                   MAGED2 variant. J Obstet Gynaecol 2019;39:395-7.  DOI
               18.      Wu X, Huang L, Luo C, Liu Y, Niu J. A case report and literature review of a novel mutation in the MAGED2 gene of a patient with
                   severe transient polyhydramnios. Front Pediatr 2021;9:778814.  DOI  PubMed  PMC
               19.      Alajjuri OA, Samaha ME, Honemeyer U, Mohammed G, Mousa NA. Balancing benefits and risks of indomethacin in the management
                   of antenatal bartter syndrome: a case report. Front Med 2022;9:870503.  DOI  PubMed  PMC
   81   82   83   84   85   86   87   88   89   90   91